Review



adaptive covid 19 treatment trial scope  (Gilead Sciences)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 99
      Buy from Supplier

    Structured Review

    Gilead Sciences adaptive covid 19 treatment trial scope
    ( 1 ) Antibodies against the spike protein (raised through vaccination or by adoptive transfer) could block severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from interacting with the angiotensin-converting enzyme 2 (ACE2) receptor on host cells. ( 2 ) Protease inhibitors against the serine protease TMPRSS2 can prevent spike protein cleavage, which is necessary for viral fusion into the host cell. Blocking either ACE2 interaction or viral fusion could prevent the virus from infecting the host cell. ( 3 ) Virus-specific memory CD8 + T cells from a previous vaccination or infection can differentiate into effector cells during rechallenge. When they identify infected cells presenting virus-specific epitopes, they degranulate and kill infected cells before they can produce mature virions. ( 4 ) In a novel treatment method that targets the cytokine storm symptoms, the blood of patients with <t>coronavirus</t> <t>disease</t> <t>2019</t> <t>(COVID-19)</t> can be passed through customized columns that are specially designed to trap pro-inflammatory cytokines, before the purified blood is passed back into patients.
    Adaptive Covid 19 Treatment Trial Scope, supplied by Gilead Sciences, used in various techniques. Bioz Stars score: 99/100, based on 15558 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/adaptive+covid+19+treatment+trial+scope/VEKLURY/pmc07187672-8-5-10
    Average 99 stars, based on 15558 article reviews
    adaptive covid 19 treatment trial scope - by Bioz Stars, 2026-10
    99/100 stars

    Images

    1) Product Images from "The trinity of COVID-19: immunity, inflammation and intervention"

    Article Title: The trinity of COVID-19: immunity, inflammation and intervention

    Journal: Nature Reviews. Immunology

    doi: 10.1038/s41577-020-0311-8

    ( 1 ) Antibodies against the spike protein (raised through vaccination or by adoptive transfer) could block severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from interacting with the angiotensin-converting enzyme 2 (ACE2) receptor on host cells. ( 2 ) Protease inhibitors against the serine protease TMPRSS2 can prevent spike protein cleavage, which is necessary for viral fusion into the host cell. Blocking either ACE2 interaction or viral fusion could prevent the virus from infecting the host cell. ( 3 ) Virus-specific memory CD8 + T cells from a previous vaccination or infection can differentiate into effector cells during rechallenge. When they identify infected cells presenting virus-specific epitopes, they degranulate and kill infected cells before they can produce mature virions. ( 4 ) In a novel treatment method that targets the cytokine storm symptoms, the blood of patients with coronavirus disease 2019 (COVID-19) can be passed through customized columns that are specially designed to trap pro-inflammatory cytokines, before the purified blood is passed back into patients.
    Figure Legend Snippet: ( 1 ) Antibodies against the spike protein (raised through vaccination or by adoptive transfer) could block severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from interacting with the angiotensin-converting enzyme 2 (ACE2) receptor on host cells. ( 2 ) Protease inhibitors against the serine protease TMPRSS2 can prevent spike protein cleavage, which is necessary for viral fusion into the host cell. Blocking either ACE2 interaction or viral fusion could prevent the virus from infecting the host cell. ( 3 ) Virus-specific memory CD8 + T cells from a previous vaccination or infection can differentiate into effector cells during rechallenge. When they identify infected cells presenting virus-specific epitopes, they degranulate and kill infected cells before they can produce mature virions. ( 4 ) In a novel treatment method that targets the cytokine storm symptoms, the blood of patients with coronavirus disease 2019 (COVID-19) can be passed through customized columns that are specially designed to trap pro-inflammatory cytokines, before the purified blood is passed back into patients.

    Techniques Used: Adoptive Transfer Assay, Blocking Assay, Infection, Purification

    Summary of approved interventional clinical trials for COVID-19 as of March 2020
    Figure Legend Snippet: Summary of approved interventional clinical trials for COVID-19 as of March 2020

    Techniques Used: Infection, Recombinant, Blocking Assay, Derivative Assay, Western Blot, Injection

    Related Articles

    Adoptive Transfer Assay:

    Article Title: The trinity of COVID-19: immunity, inflammation and intervention
    Article Snippet: NCT04273763 , The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China , Title: Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined with Standard Treatment in Patients with Suspected and Mild Novel Coronavirus Pneumonia (COVID-19) Scope: treatment of patients with COVID-19 with bromhexine hydrochloride, umifenovir hydrochloride, recombinant human interferon-α2b and favipiravir.NCT04273763 , The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China , Title: Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined with Standard Treatment in Patients with Suspected and Mild Novel Coronavirus Pneumonia (COVID-19) Scope: treatment of patients with COVID-19 with bromhexine hydrochloride, umifenovir hydrochloride, recombinant human interferon-α2b and favipiravir.. NCT04280705 , USA , Title: Adaptive COVID-19 Treatment Trial Scope: remdesivir treatment of patients with COVID-19.. ChiCTR2000030039 , Affiliated Hospital of Xuzhou Medical University , Title: Clinical Study for Infusing Convalescent Plasma to Treat Patients with New Coronavirus Pneumonia (COVID-19) Scope: infusion of polyclonal antibodies derived from immune plasma from convalescent patients with COVID-19.ChiCTR2000030039 , Affiliated Hospital of Xuzhou Medical University , Title: Clinical Study for Infusing Convalescent Plasma to Treat Patients with New Coronavirus Pneumonia (COVID-19) Scope: infusion of polyclonal antibodies derived from immune plasma from convalescent patients with COVID-19.

    Blocking Assay:

    Article Title: The trinity of COVID-19: immunity, inflammation and intervention
    Article Snippet: NCT04273763 , The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China , Title: Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined with Standard Treatment in Patients with Suspected and Mild Novel Coronavirus Pneumonia (COVID-19) Scope: treatment of patients with COVID-19 with bromhexine hydrochloride, umifenovir hydrochloride, recombinant human interferon-α2b and favipiravir.NCT04273763 , The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China , Title: Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined with Standard Treatment in Patients with Suspected and Mild Novel Coronavirus Pneumonia (COVID-19) Scope: treatment of patients with COVID-19 with bromhexine hydrochloride, umifenovir hydrochloride, recombinant human interferon-α2b and favipiravir.. NCT04280705 , USA , Title: Adaptive COVID-19 Treatment Trial Scope: remdesivir treatment of patients with COVID-19.. ChiCTR2000030039 , Affiliated Hospital of Xuzhou Medical University , Title: Clinical Study for Infusing Convalescent Plasma to Treat Patients with New Coronavirus Pneumonia (COVID-19) Scope: infusion of polyclonal antibodies derived from immune plasma from convalescent patients with COVID-19.ChiCTR2000030039 , Affiliated Hospital of Xuzhou Medical University , Title: Clinical Study for Infusing Convalescent Plasma to Treat Patients with New Coronavirus Pneumonia (COVID-19) Scope: infusion of polyclonal antibodies derived from immune plasma from convalescent patients with COVID-19.

    Infection:

    Article Title: The trinity of COVID-19: immunity, inflammation and intervention
    Article Snippet: NCT04273763 , The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China , Title: Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined with Standard Treatment in Patients with Suspected and Mild Novel Coronavirus Pneumonia (COVID-19) Scope: treatment of patients with COVID-19 with bromhexine hydrochloride, umifenovir hydrochloride, recombinant human interferon-α2b and favipiravir.NCT04273763 , The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China , Title: Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined with Standard Treatment in Patients with Suspected and Mild Novel Coronavirus Pneumonia (COVID-19) Scope: treatment of patients with COVID-19 with bromhexine hydrochloride, umifenovir hydrochloride, recombinant human interferon-α2b and favipiravir.. NCT04280705 , USA , Title: Adaptive COVID-19 Treatment Trial Scope: remdesivir treatment of patients with COVID-19.. ChiCTR2000030039 , Affiliated Hospital of Xuzhou Medical University , Title: Clinical Study for Infusing Convalescent Plasma to Treat Patients with New Coronavirus Pneumonia (COVID-19) Scope: infusion of polyclonal antibodies derived from immune plasma from convalescent patients with COVID-19.ChiCTR2000030039 , Affiliated Hospital of Xuzhou Medical University , Title: Clinical Study for Infusing Convalescent Plasma to Treat Patients with New Coronavirus Pneumonia (COVID-19) Scope: infusion of polyclonal antibodies derived from immune plasma from convalescent patients with COVID-19.

    Purification:

    Article Title: The trinity of COVID-19: immunity, inflammation and intervention
    Article Snippet: NCT04273763 , The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China , Title: Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined with Standard Treatment in Patients with Suspected and Mild Novel Coronavirus Pneumonia (COVID-19) Scope: treatment of patients with COVID-19 with bromhexine hydrochloride, umifenovir hydrochloride, recombinant human interferon-α2b and favipiravir.NCT04273763 , The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China , Title: Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined with Standard Treatment in Patients with Suspected and Mild Novel Coronavirus Pneumonia (COVID-19) Scope: treatment of patients with COVID-19 with bromhexine hydrochloride, umifenovir hydrochloride, recombinant human interferon-α2b and favipiravir.. NCT04280705 , USA , Title: Adaptive COVID-19 Treatment Trial Scope: remdesivir treatment of patients with COVID-19.. ChiCTR2000030039 , Affiliated Hospital of Xuzhou Medical University , Title: Clinical Study for Infusing Convalescent Plasma to Treat Patients with New Coronavirus Pneumonia (COVID-19) Scope: infusion of polyclonal antibodies derived from immune plasma from convalescent patients with COVID-19.ChiCTR2000030039 , Affiliated Hospital of Xuzhou Medical University , Title: Clinical Study for Infusing Convalescent Plasma to Treat Patients with New Coronavirus Pneumonia (COVID-19) Scope: infusion of polyclonal antibodies derived from immune plasma from convalescent patients with COVID-19.

    Recombinant:

    Article Title: The trinity of COVID-19: immunity, inflammation and intervention
    Article Snippet: NCT04273763 , The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China , Title: Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined with Standard Treatment in Patients with Suspected and Mild Novel Coronavirus Pneumonia (COVID-19) Scope: treatment of patients with COVID-19 with bromhexine hydrochloride, umifenovir hydrochloride, recombinant human interferon-α2b and favipiravir.NCT04273763 , The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China , Title: Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined with Standard Treatment in Patients with Suspected and Mild Novel Coronavirus Pneumonia (COVID-19) Scope: treatment of patients with COVID-19 with bromhexine hydrochloride, umifenovir hydrochloride, recombinant human interferon-α2b and favipiravir.. NCT04280705 , USA , Title: Adaptive COVID-19 Treatment Trial Scope: remdesivir treatment of patients with COVID-19.. ChiCTR2000030039 , Affiliated Hospital of Xuzhou Medical University , Title: Clinical Study for Infusing Convalescent Plasma to Treat Patients with New Coronavirus Pneumonia (COVID-19) Scope: infusion of polyclonal antibodies derived from immune plasma from convalescent patients with COVID-19.ChiCTR2000030039 , Affiliated Hospital of Xuzhou Medical University , Title: Clinical Study for Infusing Convalescent Plasma to Treat Patients with New Coronavirus Pneumonia (COVID-19) Scope: infusion of polyclonal antibodies derived from immune plasma from convalescent patients with COVID-19.

    Derivative Assay:

    Article Title: The trinity of COVID-19: immunity, inflammation and intervention
    Article Snippet: NCT04273763 , The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China , Title: Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined with Standard Treatment in Patients with Suspected and Mild Novel Coronavirus Pneumonia (COVID-19) Scope: treatment of patients with COVID-19 with bromhexine hydrochloride, umifenovir hydrochloride, recombinant human interferon-α2b and favipiravir.NCT04273763 , The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China , Title: Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined with Standard Treatment in Patients with Suspected and Mild Novel Coronavirus Pneumonia (COVID-19) Scope: treatment of patients with COVID-19 with bromhexine hydrochloride, umifenovir hydrochloride, recombinant human interferon-α2b and favipiravir.. NCT04280705 , USA , Title: Adaptive COVID-19 Treatment Trial Scope: remdesivir treatment of patients with COVID-19.. ChiCTR2000030039 , Affiliated Hospital of Xuzhou Medical University , Title: Clinical Study for Infusing Convalescent Plasma to Treat Patients with New Coronavirus Pneumonia (COVID-19) Scope: infusion of polyclonal antibodies derived from immune plasma from convalescent patients with COVID-19.ChiCTR2000030039 , Affiliated Hospital of Xuzhou Medical University , Title: Clinical Study for Infusing Convalescent Plasma to Treat Patients with New Coronavirus Pneumonia (COVID-19) Scope: infusion of polyclonal antibodies derived from immune plasma from convalescent patients with COVID-19.

    Western Blot:

    Article Title: The trinity of COVID-19: immunity, inflammation and intervention
    Article Snippet: NCT04273763 , The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China , Title: Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined with Standard Treatment in Patients with Suspected and Mild Novel Coronavirus Pneumonia (COVID-19) Scope: treatment of patients with COVID-19 with bromhexine hydrochloride, umifenovir hydrochloride, recombinant human interferon-α2b and favipiravir.NCT04273763 , The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China , Title: Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined with Standard Treatment in Patients with Suspected and Mild Novel Coronavirus Pneumonia (COVID-19) Scope: treatment of patients with COVID-19 with bromhexine hydrochloride, umifenovir hydrochloride, recombinant human interferon-α2b and favipiravir.. NCT04280705 , USA , Title: Adaptive COVID-19 Treatment Trial Scope: remdesivir treatment of patients with COVID-19.. ChiCTR2000030039 , Affiliated Hospital of Xuzhou Medical University , Title: Clinical Study for Infusing Convalescent Plasma to Treat Patients with New Coronavirus Pneumonia (COVID-19) Scope: infusion of polyclonal antibodies derived from immune plasma from convalescent patients with COVID-19.ChiCTR2000030039 , Affiliated Hospital of Xuzhou Medical University , Title: Clinical Study for Infusing Convalescent Plasma to Treat Patients with New Coronavirus Pneumonia (COVID-19) Scope: infusion of polyclonal antibodies derived from immune plasma from convalescent patients with COVID-19.

    Injection:

    Article Title: The trinity of COVID-19: immunity, inflammation and intervention
    Article Snippet: NCT04273763 , The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China , Title: Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined with Standard Treatment in Patients with Suspected and Mild Novel Coronavirus Pneumonia (COVID-19) Scope: treatment of patients with COVID-19 with bromhexine hydrochloride, umifenovir hydrochloride, recombinant human interferon-α2b and favipiravir.NCT04273763 , The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China , Title: Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined with Standard Treatment in Patients with Suspected and Mild Novel Coronavirus Pneumonia (COVID-19) Scope: treatment of patients with COVID-19 with bromhexine hydrochloride, umifenovir hydrochloride, recombinant human interferon-α2b and favipiravir.. NCT04280705 , USA , Title: Adaptive COVID-19 Treatment Trial Scope: remdesivir treatment of patients with COVID-19.. ChiCTR2000030039 , Affiliated Hospital of Xuzhou Medical University , Title: Clinical Study for Infusing Convalescent Plasma to Treat Patients with New Coronavirus Pneumonia (COVID-19) Scope: infusion of polyclonal antibodies derived from immune plasma from convalescent patients with COVID-19.ChiCTR2000030039 , Affiliated Hospital of Xuzhou Medical University , Title: Clinical Study for Infusing Convalescent Plasma to Treat Patients with New Coronavirus Pneumonia (COVID-19) Scope: infusion of polyclonal antibodies derived from immune plasma from convalescent patients with COVID-19.



    Similar Products

    adaptive covid 19 treatment trial scope  (Gilead Sciences)
    99
    Gilead Sciences adaptive covid 19 treatment trial scope
    ( 1 ) Antibodies against the spike protein (raised through vaccination or by adoptive transfer) could block severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from interacting with the angiotensin-converting enzyme 2 (ACE2) receptor on host cells. ( 2 ) Protease inhibitors against the serine protease TMPRSS2 can prevent spike protein cleavage, which is necessary for viral fusion into the host cell. Blocking either ACE2 interaction or viral fusion could prevent the virus from infecting the host cell. ( 3 ) Virus-specific memory CD8 + T cells from a previous vaccination or infection can differentiate into effector cells during rechallenge. When they identify infected cells presenting virus-specific epitopes, they degranulate and kill infected cells before they can produce mature virions. ( 4 ) In a novel treatment method that targets the cytokine storm symptoms, the blood of patients with <t>coronavirus</t> <t>disease</t> <t>2019</t> <t>(COVID-19)</t> can be passed through customized columns that are specially designed to trap pro-inflammatory cytokines, before the purified blood is passed back into patients.
    Adaptive Covid 19 Treatment Trial Scope, supplied by Gilead Sciences, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/adaptive+covid+19+treatment+trial+scope/VEKLURY/pmc07187672-8-5-10
    Average 99 stars, based on 1 article reviews
    adaptive covid 19 treatment trial scope - by Bioz Stars, 2026-10
    99/100 stars
    		  Buy from Supplier

    Image Search Results


    ( 1 ) Antibodies against the spike protein (raised through vaccination or by adoptive transfer) could block severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from interacting with the angiotensin-converting enzyme 2 (ACE2) receptor on host cells. ( 2 ) Protease inhibitors against the serine protease TMPRSS2 can prevent spike protein cleavage, which is necessary for viral fusion into the host cell. Blocking either ACE2 interaction or viral fusion could prevent the virus from infecting the host cell. ( 3 ) Virus-specific memory CD8 + T cells from a previous vaccination or infection can differentiate into effector cells during rechallenge. When they identify infected cells presenting virus-specific epitopes, they degranulate and kill infected cells before they can produce mature virions. ( 4 ) In a novel treatment method that targets the cytokine storm symptoms, the blood of patients with coronavirus disease 2019 (COVID-19) can be passed through customized columns that are specially designed to trap pro-inflammatory cytokines, before the purified blood is passed back into patients.

    Journal: Nature Reviews. Immunology

    Article Title: The trinity of COVID-19: immunity, inflammation and intervention

    doi: 10.1038/s41577-020-0311-8

    Figure Lengend Snippet: ( 1 ) Antibodies against the spike protein (raised through vaccination or by adoptive transfer) could block severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from interacting with the angiotensin-converting enzyme 2 (ACE2) receptor on host cells. ( 2 ) Protease inhibitors against the serine protease TMPRSS2 can prevent spike protein cleavage, which is necessary for viral fusion into the host cell. Blocking either ACE2 interaction or viral fusion could prevent the virus from infecting the host cell. ( 3 ) Virus-specific memory CD8 + T cells from a previous vaccination or infection can differentiate into effector cells during rechallenge. When they identify infected cells presenting virus-specific epitopes, they degranulate and kill infected cells before they can produce mature virions. ( 4 ) In a novel treatment method that targets the cytokine storm symptoms, the blood of patients with coronavirus disease 2019 (COVID-19) can be passed through customized columns that are specially designed to trap pro-inflammatory cytokines, before the purified blood is passed back into patients.

    Article Snippet: NCT04280705 , USA , Title: Adaptive COVID-19 Treatment Trial Scope: remdesivir treatment of patients with COVID-19.

    Techniques: Adoptive Transfer Assay, Blocking Assay, Infection, Purification

    Summary of approved interventional clinical trials for COVID-19 as of March 2020

    Journal: Nature Reviews. Immunology

    Article Title: The trinity of COVID-19: immunity, inflammation and intervention

    doi: 10.1038/s41577-020-0311-8

    Figure Lengend Snippet: Summary of approved interventional clinical trials for COVID-19 as of March 2020

    Article Snippet: NCT04280705 , USA , Title: Adaptive COVID-19 Treatment Trial Scope: remdesivir treatment of patients with COVID-19.

    Techniques: Infection, Recombinant, Blocking Assay, Derivative Assay, Western Blot, Injection